Modality
Degrader
MOA
Anti-Tau
Target
BCL-2
Pathway
mTOR
ALL
Development Pipeline
Preclinical
~Jun 2023
→ ~Sep 2024
Phase 1
Dec 2024
→ Mar 2028
Phase 1Current
NCT07504287
2,573 pts·ALL
2025-10→2026-05·Completed
NCT03520455
2,413 pts·ALL
2024-12→2028-03·Active
4,986 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-05-051mo awayPh2 Data· ALL
2028-03-182.0y awayPh2 Data· ALL
Trial Timeline
2025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
P1/2
Active
P1/2
Complet…
Catalysts
Ph2 Data
2026-05-05 · 1mo away
ALL
Ph2 Data
2028-03-18 · 2.0y away
ALL
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07504287 | Phase 1/2 | ALL | Completed | 2573 | DAS28 |
| NCT03520455 | Phase 1/2 | ALL | Active | 2413 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-8550 | Roche | Approved | BCL-2 | |
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| NVS-5439 | Novartis | Preclinical | BET | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| Rimaglumide | Biogen | Phase 1/2 | BCL-2 | |
| ARG-4339 | Argenx | Phase 2 | BCL-2 | |
| BGN-3305 | BeiGene | Phase 2 | BCMA | |
| GMA-729 | Genmab | Phase 2 | BCL-2 | |
| Sovarasimod | Halozyme | Phase 1/2 | WEE1 |